Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Gyeyoung Choi, Gyeongseon Shin, Seung Jin Bae

Research output: Contribution to journalComment/debate

24 Scopus citations


Although chimeric antigen receptor (CAR) T-cell therapy has shown a high response rate in lymphoma patients, its cost-effectiveness is controversial due to the high price and uncertainty of the clinical evidence. In addition to the high acquisition cost of CAR T-cell therapy, procedure and facility cost increase the financial burden considering the frequency of adverse events such as cytokine release syndrome. In clinical research, relatively short follow-up periods were used compared to traditional cancer agents. In addition, head-to-head comparative effectiveness data are unavailable, which is an important factor when evaluating the cost-effectiveness of a new treatment. Additional evidence that will compensate for the uncertainty of existing clinical data is needed for full evaluation of long-term efficacy, safety, and comparative effectiveness.

Original languageEnglish
Article number12366
JournalInternational Journal of Environmental Research and Public Health
Issue number19
StatePublished - Oct 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors.


  • CAR T-cell
  • chimeric antigen receptor T-cell therapy
  • economic evaluation
  • value


Dive into the research topics of 'Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy'. Together they form a unique fingerprint.

Cite this